Zonegran Tablet contains Zonisamide 100 mg, an anticonvulsant medication primarily indicated for the management of partial seizures in patients with epilepsy. Zonisamide exerts its therapeutic effect by stabilizing neuronal membranes and suppressing abnormal electrical activity in the brain through multiple mechanisms, including blockade of voltage-gated sodium channels and modulation of T-type calcium channels. This dual action helps reduce the frequency and severity of seizures. Zonegran is typically administered orally and may be used as monotherapy or adjunctive therapy depending on clinical requirements. The pharmacokinetic profile of Zonisamide allows for once or twice daily dosing, with a relatively long half-life facilitating steady plasma concentrations. It is important to monitor patients for potential adverse effects such as dizziness, somnolence, headache, and gastrointestinal disturbances. Rare but serious side effects include metabolic acidosis, hypersensitivity reactions, and nephrolithiasis; therefore, periodic laboratory evaluations including renal function and serum bicarbonate levels are recommended during treatment. Zonegran should be used cautiously in patients with sulfonamide allergy and renal impairment. Dose adjustments may be necessary based on therapeutic response and tolerability. As with all antiepileptic drugs, abrupt discontinuation should be avoided to prevent seizure exacerbation.